Category Reports Biotech

In its January 13, 2026 press release, BriaCell announced the durable and sustained complete resolution of a lung metastasis in a patient treated with Bria-OTS™ (off-the-shelf personalized immunotherapy). The release describes a 78-year-old woman with metastatic breast cancer who achieved complete resolution after four doses of Bria-OTS monotherapy, with confirmation out to 11 months.

Focus: FDA approval of Zycubo (copper histidinate, ex CUTX-101) as first treatment for Menkes disease in children – monetisation of milestones, royalties and potential PRV for Fortress/Cyprium.

Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Full deep dive on TENX: financials, pipeline, catalysts, shareholder structure, insider activity, dilution, analyst…

Precision oncology company built around synthetic lethality, with darovasertib in uveal melanoma and a broad pipeline (MAT2A, PRMT5, PARG, ADCs) backed by more than 1.1 billion dollars in cash and a guided runway into 2030.

Yesterday’s report framed ATRA around a PDUFA-window setup, with the assumption that the 2025 CRL was primarily a CMC/GMP story and that the ALLELE trial remained acceptable as the pivotal efficacy dataset. Today that premise is broken: the FDA has issued a second Complete Response Letter (CRL) for tabelecleucel/tab-cel in EBV+ PTLD.

As of January 10, 2026, Sana Biotechnology (NASDAQ: SANA) stands as a clinical-stage pioneer focused on the development of engineered cells as a new modality of medicine. Founded on the belief that cell therapy will follow small molecules and biologics as the "third pillar" of therapeutics, Sana has built a platform to address the two primary bottlenecks of the industry: Immune Evasion and Scalable Manufacturing.

Madrigal (MDGL) is a commercial-stage biopharma focused on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Its lead product, Rezdiffra (resmetirom), received FDA accelerated approval on March 14, 2024 as the first treatment for adults with noncirrhotic MASH with moderate to advanced fibrosis (F2–F3), to be used with diet and exercise.

Revolution Medicines, Inc. (Nasdaq: RVMD) enters the 44th Annual J.P. Morgan Healthcare Conference as a late-stage, pre-commercial oncology company focused on RAS(ON) inhibitors. The company’s FY24 results release (link) positions RVMD as “a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,” with a deep pipeline led by daraxonrasib, elironrasib and zoldonrasib.

Cellectar Biosciences (Nasdaq: CLRB) is a late-stage clinical radiopharmaceutical company built around a proprietary phospholipid drug conjugate (PDC) platform. Its lead asset, iopofosine I 131, delivers radioactive iodine-131 directly to tumor cell membranes; the most advanced program is in relapsed/refractory Waldenström macroglobulinemia (WM) after BTK inhibitor therapy, supported by the pivotal CLOVER-WaM Phase 2 data described in the company’s Form 10-K 2024 (Business section).